Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

796.80 -3.20 (-0.40%)
Streaming Delayed Price Updated: 11:34 AM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Looking Into argenx's Recent Short Interest
 
Via Benzinga
(ARGX) - Analyzing argenx's Short Interest
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at TD Cowen 45th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
From argenx SE
Via GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones. 
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
Peering Into argenx's Recent Short Interest
 
Via Benzinga
The Latest Analyst Ratings For argenx
 
Via Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion. 
Via Benzinga
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.